Table 2.
Plasma concentrations of IL-6, PDMPs, sVCAM-1, TGFβ1, and sCTLA-4 during TKI treatment of CML patients
| Patients | ||||
|---|---|---|---|---|
|
| ||||
| TKI | Imatinib | Nilotinib | Dasatinib | |
|
| ||||
| n | 8 | 6 | 18 | |
|
| ||||
| IL-6 (pg/mL) | 0 | 6.2±4.2 | 7.1±4.9 | 5.7±3.9 |
| 2M | 5.9±3.9N.S. | 6.5±4.3N.S. | 5.2±3.7N.S. | |
| 6M | 5.8±3.6N.S. | 6.6±4.7N.S. | 5.3±4.1N.S. | |
|
| ||||
| PDMPs (U/mL) | 0 | 49.8±13.3 | 52.9±15.8 | 45.2±13.6 |
| 2M | 41.3±14.7N.S. | 45.3±16.7N.S. | 32.1±9.2* | |
| 6M | 29.4±12.6* | 36.8±13.2* | 18.2±7.1** | |
|
| ||||
| sVCAM-1 (pg/mL) | 0 | 1.814±713 | 1.957±433 | 2.160±454 |
| 2M | 1.456±621* | 1.644±836N.S. | 1.210±723** | |
| 6M | 1.124±569** | 1.245±582* | 898±428*** | |
|
| ||||
| TGFβ1 (pg/mL) | 0 | 6.823±1.930 | 5.964±1.850 | 6.420±1.710 |
| 2M | 5.540±2.280* | 4.810±2.130N.S. | 3.750±1.920* | |
| 6M | 4.890±2.360* | 4.170±1.640* | 2.680±1.650** | |
|
| ||||
| sCTLA-4 (pg/mL) | 0 | 218±45 | 224±56 | 213±49 |
| 2M | 223±59N.S. | 206±70N.S. | 208±66N.S. | |
| 6M | 216±62N.S. | 220±64N.S. | 209±52N.S. | |
Notes: “n” includes the number of patients who agreed to special examinations. Data are shown as the mean ± SD. Comparisons were analyzed using Scheffe’s test. 0: before; M: months (after). P-values are for comparisons with each baseline parameter (0 vs 2M and 6M). N.S.: not significant;
*:
P<0.05;
**:
P<0.01;
***:
P<0.001.
Abbreviations: CML, chronic myelogenous leukemia; IL-6, interleukin-6; PDMPs, platelet-derived microparticles; sCTLA-4, soluble cytotoxic T lymphocyte-associated antigen-4; sVCAM-1, soluble vascular cell adhesion molecule-1; TGFβ1, transforming growth factor β1; TKI, tyrosine kinase inhibitor.